Effect Of Local Modulation In Enzymatic Homeostasis On Bone Turnover Marker Dynamics In Blood At Substituting Femur Defects With Vaterite Scaffolds

The goal of this research was the investigation of concentration changes in the blood bone turnover markers during local modulation of enzymatic homeostasis by means of targeted delivery of alkaline phosphatase (ALP) with polycaprolactone (PCL) and vaterite (VT) scaffolds implanted into the femur defects in white rats. Material and Methods ― The tests of PCL/VT/ALP scaffold implantations into the bone defects were performed on 30 white rats, and the serum of intact animals was used as the control. ELISA and multiplex assay were used to find inflammatory and bone turnover markers including monocyte chemoattractant-1, sclerostin, fibroblast growth factor-23, connective tissue growth factor (CTGF), osteoprotegerin, osteocalcin, β-сross laps and the activity of tartrate-resistant acid phosphatase-5b in the blood of experimental animals. The activity of serum ALP was tested with the conventional kinetic method. The morphology of the reparative processes was verified by microscopy of specimens taken from the implantation areas and stained with hematoxylin or eosin. Results ― The PCL/VT/ALP scaffold implantations into the bone defects of white rats caused active osteogenesis along with the steady rise in osteocalcin concentration in blood. ALP activity in the blood did not depend on the exogenous enzyme in the scaffold and rose by the 28th day after the implantations. The targeted ALP delivery into the defect area caused the rise in CTGF concentration as well as the decrease in blood sclerostin within a short time after the implantations. Conclusion ― The modulation of the local enzyme homeostasis by means of the targeted ALP delivery with PCL/VT scaffolds stimulated reparative osteogenesis within a short time after the implantations with no changes to the bloodstream or local inflammatory changes suggesting their biocompatibility and the safety in use.

Download Full-text

FP618THE ASSOCIATION OF FIBROBLAST GROWTH FACTOR - 23 AND BONE TURNOVER MARKERS ON HEMODIALYSIS PATIENTS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy104.fp618 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i250-i250

Author(s):

Ping-Hsun Wu ◽

Yi-Ting Lin ◽

Mei-Chuan Kuo ◽

Yi-Wen Chiu

Keyword(s):

Growth Factor ◽

Bone Turnover ◽

Fibroblast Growth Factor ◽

Bone Turnover Markers ◽

Fibroblast Growth Factor 23 ◽

Hemodialysis Patients ◽

Fibroblast Growth ◽

Turnover Markers

Download Full-text

Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.556 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 556-556

Author(s):

R. Aft ◽

M. Naughton ◽

K. Trinkuas ◽

M. Watson ◽

K. Weilbaecher

Keyword(s):

Zoledronic Acid ◽

Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Mineral Density ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal ◽

The Impact

556 Background: Ovarian failure secondary to adjuvant chemotherapy is known to have an adverse effect on bone mineral density and to increase bone turnover markers. The effects of chemotherapy with growth factor support in the absence of hormonal changes have not been described. The impact of zoledronic acid on these changes was also explored. Methods: We evaluated bone turnover markers in 82 women undergoing neoadjuvant chemotherapy for localized stage II/III breast cancer at initial diagnosis prior to treatment and after 4 cycles of epirubicin (75mg/m2)-docetaxel (75mg/m2) with pegylated G-CSF support with or without zoledronic acid. 47% of patients were post-menopausal and all groups were balanced for other variables. Women were randomized to receive zoledronic acid 4 mg IV every 3 weeks concurrently with chemotherapy (n=41) versus no bisphosphonate treatment (n=41). Bone turnover markers included: urinary N-telopeptide (NTx), serum bone specific alkaline phosphatase (BAP)and osteocalcin (OSTEO). Results: Women, regardless of menopausal status, who received no bisphosphonate had statistically significant increases in NTx, from baseline after 3 months of neoadjuvant chemotherapy using multivariable mixed repeated measures (p=0.0213). Women who received zoledronic acid concurrently with neoadjuvant chemotherapy had statistically significant decreases in NTx (p<0.0001), BAP (p<0.0001) and OSTEO (p=0.0295) from baseline. This is the first demonstration that anthracycline-taxane chemotherapy with growth factor support increased bone turnover markers in both post-menopausal and pre-menopausal women independent of hormone therapy, radiation therapy and surgery. Conclusions: Neoadjuvant chemotherapy with anthracycline- taxane and growth factor support increased bone resorption markers in both post-menopausal and pre-menopausal women. Zoledronic acid given concurrently with each cycle of chemotherapy reversed this increase in bone turnover markers. No significant financial relationships to disclose.

Download Full-text

Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis

Hepatology ◽

10.1002/hep.510280315 ◽

1998 ◽

Vol 28 (3) ◽

pp. 695-699 ◽

Cited By ~ 161

Author(s):

Francisco J. Gallego-Rojo ◽

Jorge L. Gonzalez-Calvin ◽

Manuel Muñoz-Torres ◽

Jose L. Mundi ◽

Ramon Fernandez-Perez ◽

...

Keyword(s):

Bone Mineral Density ◽

Growth Factor ◽

Bone Turnover ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Serum Insulin ◽

Insulin Like Growth Factor ◽

Mineral Density ◽

Factor I ◽

Turnover Markers

Download Full-text

Physical Activity in Relation to Serum Sclerostin, Insulin-Like Growth Factor-1, and Bone Turnover Markers in Healthy Premenopausal Women: A Cross-Sectional and a Longitudinal Study

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2011-3361 ◽

2012 ◽

Vol 97 (10) ◽

pp. 3691-3699 ◽

Cited By ~ 67

Author(s):

Mohammed-Salleh M. Ardawi ◽

Abdulrahim A. Rouzi ◽

Mohammed H. Qari

Keyword(s):

Physical Activity ◽

Longitudinal Study ◽

Growth Factor ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Premenopausal Women ◽

Insulin Like Growth Factor ◽

Cross Sectional ◽

Turnover Markers

Download Full-text

Fibroblast Growth Factor 21 Is Associated With Bone Mineral Density, but not With Bone Turnover Markers and Fractures in Chinese Postmenopausal Women

Journal of Clinical Densitometry ◽

10.1016/j.jocd.2018.08.005 ◽

2019 ◽

Vol 22 (2) ◽

pp. 179-184 ◽

Cited By ~ 3

Author(s):

WeiWei Hu ◽

Jinwei He ◽

Wenzhen Fu ◽

Chun Wang ◽

Hue Yue ◽

...

Keyword(s):

Bone Mineral Density ◽

Growth Factor ◽

Bone Turnover ◽

Fibroblast Growth Factor ◽

Bone Turnover Markers ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Mineral Density ◽

Chinese Postmenopausal Women ◽

Turnover Markers

Download Full-text

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

Clinical Kidney Journal ◽

10.1093/ckj/sfz034 ◽

2019 ◽

Vol 13 (1) ◽

pp. 75-84 ◽

Cited By ~ 3

Author(s):

Myles Wolf ◽

Geoffrey A Block ◽

Glenn M Chertow ◽

Kerry Cooper ◽

Bruno Fouqueray ◽

...

Keyword(s):

Growth Factor ◽

Bone Turnover ◽

Secondary Hyperparathyroidism ◽

Fibroblast Growth Factor ◽

Bone Turnover Markers ◽

Calcium Supplementation ◽

Fibroblast Growth Factor 23 ◽

Fibroblast Growth ◽

Secondary Analyses ◽

Turnover Markers

Abstract Background Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown. Methods To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n = 509) versus placebo (n = 514) and etelcalcetide (n = 340) versus cinacalcet (n = 343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23 in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide. Results Etelcalcetide reduced FGF23 [median % change (quartile 1–quartile 3)] from baseline to the end of the trial significantly more than placebo [–56% (–85 to –7) versus +2% (–40 to +65); P < 0.001] and cinacalcet [–68% (–87 to –26) versus –41% (–76 to +25); P < 0.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the FGF23-lowering effects of etelcalcetide. Conclusion These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium.

Download Full-text